Nitika Mor | Drug Discovery and Development | Best Researcher Award

Posted on 03/05/202503/05/2025 by sciencefather

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Dr. Nitika Mor, Baba Mastnath University, Asthal Bohar, Rohtak (HR), India

Dr. Nitika Mor is an accomplished Assistant Professor of Chemistry at Baba Mastnath University, Rohtak, with a Ph.D. in Pharmaceutical Chemistry from Kurukshetra University. Her research focuses on drug delivery systems, traditional medicinal formulations, and molecular docking. She has published 14 research papers, authored a book chapter, holds two patent publications (one granted), and has received multiple awards including the UGC-CSIR JRF/SRF and Best Poster Award. With technical expertise in synthesis, biological assays, and in-silico studies, Dr. Mor is a dynamic contributor to pharmaceutical research and innovation.

Publication Profile

Google Scholar

Education

Dr. Nitika Mor is a dedicated researcher with a Ph.D. in Chemistry from Kurukshetra University (2017–2022), where she focused her thesis on the Design, Characterization, and In-Vitro Studies of Sustained Release Delivery Systems for Curcumin under the guidance of Dr. Neera Raghav. 🎓 She holds an M.Sc. in Organic Chemistry (2013–2015) from Hindu College, Sonipat, affiliated with Maharishi Dayanand University, Rohtak. 🧪 Her academic journey began with a B.Sc. in Physics, Chemistry, and Mathematics (2010–2013) from Hindu Girls College, Sonipat. 📚 Dr. Mor’s educational background reflects a strong foundation in science and innovative pharmaceutical research.

Experience

Dr. Nitika Mor is currently serving as an Assistant Professor in the Department of Chemistry at Baba Mastnath University, Rohtak, since February 1, 2023. 🏛️ With her strong academic foundation and research expertise in pharmaceutical and organic chemistry, she brings innovative teaching methods and deep subject knowledge to the classroom. 🧪 Her role involves mentoring students, delivering engaging lectures, and contributing to the academic growth of the department. 📚 Dr. Mor’s commitment to education and passion for chemistry make her a valuable asset to the university’s faculty. ✨ She continues to inspire budding scientists through her teaching and guidance.

Awards

Dr. Nitika Mor has received several prestigious awards and fellowships in recognition of her academic excellence and research potential. She qualified the UGC-CSIR JRF (Chemical Sciences) in June 2016 with an impressive All India Rank of 65. 🇮🇳 She was awarded the Junior Research Fellowship (JRF) from October 2017 to September 2019, followed by the Senior Research Fellowship (SRF) from October 2019 to March 2022 by UGC-CSIR India to support her Ph.D. journey. 🔬 In 2018, she received the Best Poster Presentation Award at the 9th National Conference on RACES-2018 held at MMM College, Patiala, Punjab.

Research Focus

Dr. Nitika Mor specializes in pharmaceutical and biomedical sciences, with a strong research focus on natural polymer-based oral drug delivery systems. Her work emphasizes the use of biopolymers like cellulose, pectin, carrageenan, and alginate for sustained release formulations, particularly for curcumin. She explores modifications of polysaccharides and curcumin derivatives to improve bioavailability, pharmacokinetics, and therapeutic efficacy. Her contributions also span phytochemistry, investigating medicinal plants like Ashwagandha and Garlic for their pharmacological benefits. Dr. Mor integrates green chemistry, molecular modeling, and clinical insights into her innovative drug delivery strategies.

Publication Top Notes

Recent advances in cellulose, pectin, carrageenan and alginate-based oral drug delivery systems

Some cetyltrimethylammonium bromide modified polysaccharide supports as sustained release systems for curcumin

Design and development of carboxymethylcellulose ester of curcumin as sustained release delivery system in liver

Synthesis of propynyloxy substituted some novel aurones as potent cathepsin B inhibitors

Alginate hydrogels: Sustained release system to analyze the effect of traditional excipients on curcumin availability

Study on enhanced serum protein protecting and anti-cathepsin activities of various curcumin formulations containing traditional excipients and bio-enhancers

In-vitro simulation of modified-alginate ester as sustained release delivery system for curcumin

Curcumin, the panacea: A review on advancement to solve pharmaco-kinetic problems.

A review: Phytochemicals and bioactivities of Ashwagandha (Withania somnifera).

yang huanzhi | Pharmacology | Best Researcher Award

Posted on 16/04/202516/04/2025 by sciencefather

yang huanzhi | Pharmacology | Best Researcher Award

Dr. yang huanzhi, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China, China

Dr. Huanzhi Yang is a Ph.D. candidate in Food Science and Engineering at China Agricultural University (2019–2025) 🎓, focusing on food nutrition, natural products, and chronic disease prevention. With a strong academic background from Hunan Agricultural University and Huaihua University, his research spans functional food development, gut health, and antioxidants. He has authored multiple high-impact publications 📝, holds several international patents 🧪, and has collaborated on national food science projects. Recognized for his innovation and excellence, Dr. Yang has received numerous scholarships, awards, and honors 🏆, showcasing his commitment to scientific advancement and food health solutions.

Publication Profile

Scopus

Education

Dr. Yang Huanzhi 🎓 is currently pursuing a Ph.D. in Engineering at China Agricultural University (2019.09–2025.06), specializing in Food Science and Engineering under the guidance of Prof. Xiaojun Liao 🍎. He earned his Master’s degree in Bioengineering from Hunan Agricultural University (2016.09–2018.06), mentored by Prof. Guoping Peng 🧬. Dr. Yang began his academic journey at Huaihua University, where he completed his Bachelor’s degree in Bioengineering (2012.09–2016.06) 📘. With a solid foundation in food and biosciences, his research focuses on advancing food science and nutritional engineering for a healthier future 🌱.

Experience

Dr. Yang Huanzhi’s research focuses on food nutrition and health 🍽️, emphasizing the role of natural products in preventing and controlling chronic diseases 💊. With a passion for improving public well-being, he explores the bioactive components in natural sources 🌿 and their potential in promoting long-term health. His work contributes to the development of functional foods that not only nourish but also serve therapeutic purposes 🥦. By integrating nutritional science with innovative food engineering, Dr. Yang aims to create sustainable, health-promoting dietary solutions for modern lifestyles 🧠❤️. His dedication is shaping the future of preventive nutrition and wellness.

Awards

Dr. Yang Huanzhi has been recognized for his outstanding academic and research achievements 🌟. From 2020 to 2024, he consistently received the “Second Class Scholarship” 🏅 for five consecutive years during his doctoral studies at China Agricultural University. In 2022, he earned the second prize in the 3rd “Xingnong Cup” Innovation and Entrepreneurship Competition 💡. His dedication to safety and responsibility earned him the honorary title of Excellent Laboratory Safety Officer for two consecutive years (2021–2022) 🧪🛡️. Additionally, in 2019, his master’s work was honored with the “Excellent Master’s Thesis” award from Hunan Agricultural University 📜🏆.

Research Focus

Dr. Yang Huanzhi focuses on nutraceuticals, gut microbiota, and inflammation-related diseases. His research delves into how natural plant-based compounds—particularly polyphenols from CiLi (Rosa roxburghii Tratt.)—can modulate the gut microbiota-lipid mediator-immunity axis to alleviate chronic inflammatory conditions such as colitis. 🌿 His work bridges phytochemistry, immunology, and microbiome research, emphasizing the therapeutic potential of functional foods and dietary interventions. 🧫💊 By uncovering the molecular pathways through which CiLi polyphenols influence gut health and immune regulation, Dr. Huanzhi contributes to the advancement of integrative medicine and functional nutrition in disease prevention and treatment.

Publication Top Notes

CiLi (Rosa roxburghii Tratt.) polyphenols improve colitis via gut microbiota-lipid mediator-immunity axis

Minglong Yan | Drug Discovery and Development | Young Scientist Award

Posted on 07/04/202507/04/2025 by sciencefather

Minglong Yan | Drug Discovery and Development | Young Scientist Award

Mr. Minglong Yan, Chinese Academy of Science, China

Mr. Minglong Yan holds advanced degrees in his field, with a distinguished academic and professional background in scientific research and innovation. He has completed multiple research projects, contributed to numerous indexed journal publications, and holds editorial appointments in reputable journals. With a strong citation index in SCI and Scopus, he is actively engaged in industry-sponsored projects, collaborative studies, and has authored several ISBN-registered books 📚. His expertise spans diverse research areas, contributing significantly to scientific advancement and innovation, including patents published or in process. Mr. Yan is also a member of esteemed professional organizations, fostering academic excellence globally 🌐.

Publication Profile

orcid

Education

Mr. Minglong Yan 🎓 holds advanced degrees in engineering and materials science, with a strong foundation in innovative research and development. With over a decade of professional experience, he has contributed significantly to the fields of advanced materials and nanotechnology. 🧪 His work has been recognized in peer-reviewed journals and international conferences. As a dedicated academic, he has mentored numerous students and collaborated on global research initiatives. 🌏 Mr. Yan’s achievements include multiple research grants and awards that highlight his impactful contributions to science and technology. 🔬 His commitment to excellence continues to inspire innovation and academic advancement.

Experience

Mr. Minglong Yan 🤝 has built strong interdisciplinary collaborations with researchers from institutions across various countries, fostering global scientific exchange and innovation. 🌐 His collaborative efforts have led to numerous joint publications, international workshops, and the development of data-sharing platforms 📊 that enhance research transparency and accessibility. Notably, his work on a multi-institutional study focused on advanced nanomaterials 🧬 gained considerable recognition within the research community, showcasing the power of international teamwork. These partnerships not only broaden the impact of his research but also contribute to the advancement of science through shared knowledge and collective expertise.

Professional Memberships

Mr. Minglong Yan 🧑‍🔬 is an active member of the IEEE ⚙️ and the Materials Research Society (MRS) 🔬, two prestigious organizations that support scientific innovation and collaboration. Through these memberships, he engages with leading experts in his field, stays updated on emerging research trends 📈, and participates in global conferences and symposiums 🌍. These affiliations provide valuable platforms for networking, professional development, and interdisciplinary exchange. Mr. Yan’s involvement in such renowned societies highlights his dedication to advancing science and technology while remaining connected to the broader research community.

Research Focus

Mr. Minglong Yan focuses on smart surface engineering, particularly the development of anti-biofouling materials, self-healing coatings, and slippery lubricant-infused surfaces (SLIPS). His research merges materials science, nanotechnology, and green chemistry to design photocatalytic, self-renewable, and multi-functional coatings. These materials aim to resist microbial adhesion and environmental fouling, with long-term durability and ecological safety. His work is especially impactful in marine applications, medical devices, and membrane technology. 🧪🦠💧🔄⚙️ His innovative use of Schiff-base chemistry, MOFs, organogels, and paraffin frameworks pushes boundaries in dynamic surface behavior and bio-inspired antifouling strategies.

Publication Top Notes

Designing a photocatalytic and self-renewed g-C3N4 nanosheet/poly-Schiff base composite coating towards long-term biofouling resistance

Cinnamaldehyde grafted porous Aerogel-Organ gel liquid infused surface for achieving difunctional long-term dynamic antifouling

Multi-stimulus Response Behavior of Biomimetic Autocrine Waxy Materials for Potential Self-Constructing Surface Microstructures

Antibacterial-renew dual-function anti-biofouling strategy: Self-assembled Schiff-base metal complex coatings built from natural products

Foaming process-induced porous silicone-based organogel for low biofouling adhesion with improved long-term stability

Cross‐Linked but Self‐Healing and Entirely Degradable Poly‐Schiff Base Metal Complex Materials for Potential Anti‐Biofouling

Designing a MOF-based slippery lubricant-infused porous surface with dual functional anti-fouling strategy

Yu Liu | Drug Discovery and Development | Best Researcher Award

Posted on 03/04/202503/04/2025 by sciencefather

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Tang Jin-Bao | Pharmacology | Best Researcher Award

Posted on 18/02/202518/02/2025 by sciencefather

Tang Jin-Bao | Pharmacology | Best Researcher Award

Prof. Dr Tang Jin-Bao,Shandong Second Medical University,China

Prof. Dr. Jin-Bao Tang, a licensed pharmacist in China, is a professor at Shandong Second Medical University. He earned his Ph.D. in Microbial and Biochemical Pharmacy from Shandong University in 2023. An esteemed graduate sponsor in Shandong Province, he specializes in Biotechnological Pharmaceutics and Pharmaceutical Engineering. His research focuses on developing novel immunoassay biosensors for proteins and peptides. With multiple high-impact publications in Food Chemistry and Analytical Bioanalytical Chemistry, he has pioneered advanced immunosensor technologies. His innovative contributions to biosensor development enhance precision in food safety and biomedical analysis. 🔬📚

Publication Profile

Scopus

Education

Prof. Dr. Jin-Bao Tang 🎓 holds a Doctorate in Microbial and Biochemical Pharmacy from Shandong University (2023) and is a licensed pharmacist in China. As a distinguished professor at Shandong Second Medical University, he plays a vital role in educating future pharmaceutical professionals in Biotechnological Pharmaceutics and Pharmaceutics Engineering 🧪. His dedication to academia is evident through his mentorship and contributions to pharmaceutical sciences. Recognized as an excellent graduate sponsor of Shandong Province 🏆, Dr. Tang’s expertise and commitment continue to shape the next generation of researchers and industry leaders in the field of pharmacy. 💊

Scientific Community

Prof. Dr. Jin-Bao Tang 🧑‍🔬 has made a significant impact in the scientific community through his groundbreaking research in biotechnology and pharmacology. His publications appear in prestigious journals such as Food Chemistry, International Journal of Biological Macromolecules, Food Control, and Analytical Bioanalytical Chemistry 📚. His collaborative work has led to advancements in oriented antibody immobilization, photoconjugation strategies, and biosensor technology 🧪, with profound implications for public health, biotechnology, and pharmacological applications. Through his innovative contributions, Prof. Tang continues to shape the future of pharmaceutical sciences, enhancing diagnostic and therapeutic approaches for global healthcare. 🌍💊

Research Contributions

Prof. Dr. Tang Jin-Bao’s research revolves around developing novel immunoassay biosensors for protein and peptide detection 🧪🔬. His pioneering work has significantly advanced biosensing technology, particularly in food safety and biomedical analysis 🍎⚕️. Over the past five years, his high-impact publications have introduced innovative techniques such as electrochemical immunosensors for aflatoxin detection ⚡, bioluminescent immunoassays using antibody-nanoluciferase conjugates ✨, and Fc-specific antibody modifications for enhanced biosensor performance 🧫. Additionally, his photoconjugation strategies have led to stable fluorescent antibody fabrication 🌟. These breakthroughs contribute immensely to food safety, pharmaceutical analysis, and immunodiagnostics, demonstrating the real-world impact of his research. 🚀

Research Focus

Prof. Dr. Jin-Bao Tang’s research primarily focuses on biosensors 🧪, immunoassays 🏥, and antibody engineering 🧬 for food safety and biomedical applications. His work involves developing electrochemical immunosensors ⚡, bioluminescent assays 💡, and advanced antibody modifications 🏗️ to enhance the detection of harmful contaminants like aflatoxin B1 🍄⚠️. He explores oriented antibody immobilization 🎯 to improve sensitivity and specificity in bioanalytical methods. Additionally, his research extends to drug delivery systems 💊, particularly in pulsatile release formulations ⏳, using innovative polymers. His contributions advance food safety 🥗, biomedical diagnostics 🏥, and pharmaceutical technologies 💊 for global health and safety.

Publication Top Notes

A facile and effective electrochemical immunosensor based on controlled and oriented immobilization of natural antibodies for sensitive detection of aflatoxin B₁

Development of a bioluminescent immunoassay based on Fc-specific conjugated antibody–nanoluciferase immunoreagents for determining aflatoxin B₁

Fabrication of cysteine-modified antibodies with Fc-specific conjugation for covalent and oriented immobilization of native antibodies

Preparation of enteric capsules with pulsatile drug delivery potential using pullulan and polyacrylic acid resin III

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Posted on 01/02/202501/02/2025 by sciencefather

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Dr Shanthi Veerappapillai, Vellore Institute of Technology, India

Dr. Shanthi Veerappapillai is a distinguished Professor at VIT University, specializing in Bioinformatics and Computational Biology. With a Ph.D. from VIT, her research interests include computational protein analysis, drug resistance studies, and virtual screening, particularly focusing on infectious diseases like HIV and tuberculosis. She has led multiple funded research projects and published over 130 peer-reviewed articles. Dr. Veerappapillai has been recognized with awards like the Women Achiever Award for Sponsored Research Excellence (2020) and has supervised numerous Ph.D. graduates. Her dedication to education and research is also reflected in her active participation in conferences and professional societies. 👩‍🔬📚💻🌍

Publication Profile

Google Scholar

Education Qualification

Dr. Shanthi Veerappapillai holds a Ph.D. in Bioinformatics from VIT University, Tamil Nadu, India, and an M.Tech in Chemical Process and Design from SASTRA University, Tamil Nadu, India. She also earned a B.Tech in Chemical Engineering from EGS Pillai Engineering College, Bharathidasan University, Tamil Nadu, India. With a strong foundation in both chemical engineering and bioinformatics, Dr. Veerappapillai brings a multidisciplinary approach to her research and academic work. Her diverse academic background equips her with the expertise to bridge the gap between technology and biology, contributing to advancements in various scientific fields. 🧬⚙️🎓

Leadership in Research

Dr. Shanthi Veerappapillai is a dedicated scientist with extensive leadership experience as Principal Investigator (PI) in multiple prominent projects. Her research spans critical areas such as drug repurposing strategies and cancer research, showcasing her expertise in advancing both medical and computational biology. Through her work, she has contributed significantly to the development of innovative therapeutic approaches, emphasizing her commitment to enhancing healthcare and medical research. Her ability to lead and collaborate on large-scale projects underscores her impact in the field, making her a valuable asset in shaping the future of medical science and computational biology. 🧬🔬💊

Mentorship and Teaching

Dr. Shanthi Veerappapillai is a distinguished academic with vast experience in supervising successful Ph.D. candidates and teaching specialized subjects in biotechnology and bioinformatics. Her dedication to fostering academic development is evident in her role as a mentor to future researchers. With a passion for guiding students through advanced research topics, she has contributed significantly to shaping the next generation of experts in her field. Her work in biotechnology and bioinformatics continues to inspire students, encouraging innovation and critical thinking in these dynamic disciplines. 👩‍🔬📚🎓🔬👩‍💻

Community Engagement

Dr. Shanthi Veerappapillai is a dedicated academician who has made significant contributions to the scientific community through her active involvement in organizing conferences and workshops. As a member of various professional bodies, Dr. Veerappapillai continuously strengthens her presence in the academic world, sharing her expertise and collaborating with fellow researchers. Her commitment to advancing knowledge and fostering professional connections has had a lasting impact on her field. With a focus on promoting growth in the academic and scientific community, Dr. Veerappapillai’s efforts continue to inspire others. 🌍🧑‍🏫📚

Awards and Achievement

Dr. Shanthi Veerappapillai is a distinguished researcher with 131 peer-reviewed journal articles and an H-index of 14. She received the Best Chapter Award from BRSI-VIT for her exceptional contributions in 2023. She was honored with the Women Achiever Award for Sponsored Research Excellence in 2020 and has been a Research Fellow at INTI International University, Malaysia since June 2023. Dr. Veerappapillai’s academic journey includes producing 100% results in Chemical Engineering Thermodynamics courses and securing university ranks and prizes for academic excellence. She has also received several accolades, including a Best Poster Presentation Award at VIT University. 🏆📚👩‍🔬🌟

Research Focus

Dr. V. Shanthi’s research primarily focuses on molecular simulation, bioinformatics, and computational approaches to drug discovery. She has explored mechanisms of drug resistance, particularly in influenza virus neuraminidase, using molecular simulations to understand oseltamivir resistance. Her work also spans polypharmacology, investigating therapeutic agents for non-small cell lung cancer, and the identification of potential inhibitors for various viruses like H5N1. Additionally, she has contributed to bioprocess industry applications, drug repurposing, and plant-based therapeutic compounds. Her research aims at enhancing drug design, discovering novel therapeutic agents, and understanding the molecular interactions that govern drug efficacy. 🔬💊🦠💡

Publication Top Notes

Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach

Current progress and future perspectives of polypharmacology: From the view of non-small cell lung cancer

Bioactive Amento flavone isolated from Cassia fistula L. leaves exhibits therapeutic efficacy

Application of heat exchangers in bioprocess industry: a review

Multi-dimensional screening strategy for drug repurposing with statistical framework—a new road to influenza drug discovery

Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach

Role of the cation-π interaction in therapeutic proteins: A comparative study with conventional stabilizing forces

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Posted on 20/01/202522/01/2025 by sciencefather

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat